TERMIS 2021 | Addressing challenges in cardiac tissue engineering

Transplantation is the current solution for patients with heart failure, but can result in organ rejection and requires immunosuppressive medication. Carmine Gentile, PharmD/PhD, FAHA, University of Technology Sydney, Sydney, Australia, comments on remaining barriers to successfully developing tissue engineered tissue for cardiovascular disease. Replicating the vascular network of the heart, as well the contractile force of the host cardiac tissue remains a challenge for researchers. Dr Gentile additionally highlights clinical translation issues associated with tissue engineering. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).